View Older Stories View More Recent Stories

Jun 9, 2023 06:25PM Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Jun 5, 2023 05:54AM Allogene Therapeutics (ALLO) Presents Updated ALLO-501/501A Phase 1 Data
Jun 3, 2023 09:00AM Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2023 08:30AM Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
May 18, 2023 08:00AM Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
May 11, 2023 11:50AM Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
May 3, 2023 04:02PM Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Apr 26, 2023 10:06AM Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 26, 2023 10:06AM Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2023 08:30AM Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Apr 25, 2023 08:30AM Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Apr 20, 2023 04:06PM Allogene Therapeutics (ALLO) Appoints Timothy Moore as CTO
Apr 20, 2023 04:05PM Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Apr 20, 2023 04:05PM Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Apr 17, 2023 10:15AM Allogene Therapeutics (ALLO) Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research
Apr 17, 2023 10:15AM Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Apr 17, 2023 10:15AM Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Apr 13, 2023 08:30AM Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Apr 13, 2023 08:30AM Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Mar 30, 2023 08:30AM Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Mar 30, 2023 08:30AM Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Mar 14, 2023 05:30PM Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Mar 14, 2023 05:30PM Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Mar 2, 2023 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Mar 2, 2023 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Mar 1, 2023 08:31AM Allogene Therapeutics (ALLO) Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement
Mar 1, 2023 08:30AM Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 
Mar 1, 2023 08:30AM Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 
Feb 28, 2023 04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 28, 2023 04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 21, 2023 08:30AM Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Feb 21, 2023 08:30AM Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Feb 1, 2023 02:55PM Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
Feb 1, 2023 02:55PM Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
Jan 25, 2023 08:30AM Allogene Therapeutics (ALLO) Announces Publication Supporting DLL3 as a Potential AlloCAR T Target
Jan 25, 2023 08:30AM Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Jan 25, 2023 08:30AM Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Jan 24, 2023 08:31AM Allogene Therapeutics (ALLO) Announces Publication of Data from its Phase 1 UNIVERSAL Study of ALLO-715
Jan 24, 2023 08:30AM Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Jan 24, 2023 08:30AM Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Jan 17, 2023 04:05PM Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Jan 17, 2023 04:05PM Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Jan 4, 2023 08:30AM Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 4, 2023 08:30AM Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 08:00AM Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Jan 3, 2023 08:00AM Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Nov 29, 2022 03:30PM Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
Nov 29, 2022 03:30PM Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
Nov 10, 2022 09:00AM Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Nov 10, 2022 09:00AM Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
View More Recent Stories View Older Stories